# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sun Yat-sen (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET016-SYN
- Date: 2026-08-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Wen-Li Huang, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Before cycle 4: restaging CT, tumor marker, side effects, and genomic profiling result. **S**

## History of present illness

Mr. Sun returns before cycle 4, nine weeks after starting treatment. He has had all three cycles on schedule. He is nauseated on the two days after each infusion, which ondansetron controls, and tired for three or four days after each day-8 dose; otherwise he works most days. He has no diarrhea, rash, cough or breathlessness, no numbness or tingling, and no ringing in the ears or change in hearing. The ache under his ribs is 1 to 2 of 10 and he takes acetaminophen only a few times a week. He has seen the palliative care team twice and says it helped him sleep and think about his priorities. The restaging CT four days ago and the HBV DNA drawn with it are back, and so is the genomic profiling of his tumor. **S**

| Element | Detail |
|---|---|
| Cycles | Three, all on schedule |
| Side effects | Nausea two days after infusions, controlled; tiredness after day-8 doses |
| Immune-related symptoms | None |
| Pain | 1 to 2 of 10; acetaminophen a few times a week |
| Palliative care | Two visits; sleep and coping better |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired after day-8 doses; weight 59.2 kg; no fever |
| Gastrointestinal | Positive | Nausea for two days after infusions; no diarrhea or jaundice |
| Ears, nose, mouth, and throat | Negative | No tinnitus or hearing change; no mouth sores |
| Respiratory | Negative | No cough or breathlessness |
| Integumentary | Negative | No rash or itching |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood steadier; sleeping better; PHQ-9 5 |

7 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a day **S**
- Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycle **S**
- Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycle **S**
- Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycle **S**
- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/78 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 59.2 kg; BMI 21.7 kg/m². All vital signs are synthetic.

White cells: 4.6 10*3/uL; Neutrophils: 2.4 10*3/uL; Hemoglobin: 10.9 g/dL (low); Platelets: 188 10*3/uL; Sodium: 136 mmol/L; Potassium: 4 mmol/L; Creatinine: 0.92 mg/dL; eGFR: 97 mL/min/1.73 m²; Glucose: 94 mg/dL; Magnesium: 1.7 mg/dL; Albumin: 3.6 g/dL; Total bilirubin: 0.7 mg/dL; Alkaline phosphatase: 158 U/L (high); AST: 34 U/L; ALT: 30 U/L; TSH: 2.4 mIU/L; CA 19-9: 168 U/mL (high); PHQ-9: 5; ECOG performance status: 1. All results are synthetic.

## Change since baseline

- White cells: 7.9 10*3/uL at baseline, 4.6 10*3/uL at this visit **S**
- Hemoglobin: 12.6 g/dL (low) at baseline, 10.9 g/dL (low) at this visit **S**
- Platelets: 342 10*3/uL at baseline, 188 10*3/uL at this visit **S**
- Sodium: 137 mmol/L at baseline, 136 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4 mmol/L at this visit **S**
- Creatinine: 0.86 mg/dL at baseline, 0.92 mg/dL at this visit **S**
- eGFR: 101 mL/min/1.73 m² at baseline, 97 mL/min/1.73 m² at this visit **S**
- Glucose: 98 mg/dL at baseline, 94 mg/dL at this visit **S**
- Albumin: 3.4 g/dL (low) at baseline, 3.6 g/dL at this visit **S**
- Total bilirubin: 0.9 mg/dL at baseline, 0.7 mg/dL at this visit **S**
- Alkaline phosphatase: 212 U/L (high) at baseline, 158 U/L (high) at this visit **S**
- AST: 48 U/L (high) at baseline, 34 U/L at this visit **S**
- ALT: 41 U/L at baseline, 30 U/L at this visit **S**
- CA 19-9: 412 U/mL (high) at baseline, 168 U/mL (high) at this visit **S**
- ECOG performance status: 1 at baseline, 1 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin, well; blood pressure 122/78, pulse 82; weight 59.2 kg; no jaundice |
| Abdomen | Liver edge firm, 3 cm below the right costal margin, smaller than at diagnosis; no ascites |
| Skin | No rash; port site clean |
| Neurological | Light touch and vibration normal in the fingers and toes |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Gallbladder adenocarcinoma, stage IVB, on chemoimmunotherapy** (C23). Restaging CT: the gallbladder and liver mass is 5.6 cm (7.1 cm at baseline), the hepatoduodenal nodes 1.1 and 0.9 cm, and the peritoneal nodules smaller; no new lesions. The sum of target lesions has fallen 24%, stable disease by RECIST with shrinkage. CA 19-9 168 U/mL, from 498. Side effects grade 1 (nausea, fatigue); hemoglobin 10.9 g/dL (grade 1 anemia). Genomic profiling: microsatellite stable and mismatch-repair proficient, HER2 not amplified, no FGFR2 fusion, IDH1, BRAF and KRAS wild-type, a TP53 mutation, tumor mutational burden 4 per megabase: no targeted treatment option now. TSH 2.4 and glucose 94 mg/dL. **S**
   - Cycle 4 today, unchanged doses.
   - Continue to 8 cycles, then durvalumab every 4 weeks.
   - Restaging CT after cycle 7.
2. **Peritoneal metastases** (C78.6). Smaller on CT; no ascites. **S**
   - Followed on restaging CT.
3. **Resolved hepatitis B infection** (Z86.19). HBV DNA undetectable four days ago; ALT 30 U/L. No reactivation. **S**
   - Repeat HBV DNA and ALT in about 3 months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | CT of the chest, abdomen and pelvis | At staging, then every 2 to 3 months on treatment | Completed today | Four days ago: mass 5.6 cm from 7.1 cm; nodes and peritoneal nodules smaller; no new lesions; stable disease, sum down 24% |
| Laboratory | CA 19-9 (and CEA when raised) | At diagnosis, then with each cycle or restaging | Completed today | CA 19-9 168 U/mL, from 498 |
| Laboratory | Blood count with neutrophils | Before every dose (days 1 and 8) | Completed today | White cells 4.6, neutrophils 2.4, hemoglobin 10.9 g/dL (grade 1 anemia), platelets 188; adequate for treatment |
| Laboratory | Creatinine and eGFR | Before every dose (days 1 and 8) | Completed today | Creatinine 0.92 mg/dL, eGFR 97 |
| Laboratory | Magnesium and potassium | Before every dose (days 1 and 8) | Completed today | Magnesium 1.7 mg/dL (lower limit), potassium 4.0 mmol/L, sodium 136 mmol/L; dietary magnesium advised |
| Laboratory | Liver tests (bilirubin, alkaline phosphatase, AST, ALT, albumin) | Before every dose (days 1 and 8) | Completed today | Bilirubin 0.7 mg/dL, alkaline phosphatase 158, AST 34, ALT 30 U/L, albumin 3.6 g/dL; improving |
| Laboratory | TSH | Baseline, then every 4 to 6 weeks on durvalumab | Completed today | 2.4 mIU/L |
| Laboratory | Glucose | Baseline, then with each pre-dose chemistry panel on durvalumab | Completed today | 94 mg/dL; on the standing pre-dose order since cycle 1 day 8, after the gap at cycle 1 day 1 |
| Laboratory | HBV DNA and ALT (resolved hepatitis B) | Every 3 months during treatment and for 6 to 12 months after | Completed today | HBV DNA undetectable four days ago; ALT 30 U/L |
| Medication safety | Immune-related side effects (diarrhea, rash, cough or breathlessness, fatigue, endocrine symptoms) | Every visit | Completed today | No diarrhea, rash, cough, breathlessness or endocrine symptoms |
| Medication safety | Chemotherapy side effects: nausea, fatigue, neuropathy, hearing | Every visit | Completed today | Grade 1 nausea and fatigue; no neuropathy |
| Examination | Hearing (cisplatin) | Baseline before cisplatin, then by symptoms each cycle | Completed today | No tinnitus or hearing change; whispered voice heard |
| Survey | ECOG performance status | Every visit | Completed today | ECOG 1 |
| Examination | Weight and nutrition | Every visit | Completed today | 59.2 kg, 0.8 kg below the start of treatment |
| Survey | Pain | Every visit | Completed today | 1 to 2 of 10 |
| Survey | Distress and depression (PHQ-9) | At each change in treatment or status | Completed today | PHQ-9 5 |
| Laboratory | Comprehensive genomic profiling of tumor tissue | At diagnosis of advanced disease | Completed today | No targetable alteration; microsatellite stable |
| Referral | Specialist palliative care | From the diagnosis of advanced cancer | Completed today | Two visits; ongoing every 3 to 4 weeks |

## Goal progress

- Tissue diagnosis and complete staging within four weeks of the first visit. Outcome by 2026-06-01: Biopsy diagnosis in nine days and staging complete by laparoscopy in about three and a half weeks. **S**
- Right upper abdominal pain at 3 of 10 or less, with full days of work possible (ECOG 0 to 1). In progress; target 2026-10-26. **S**
- Weight held within 2 kg of the weight at the start of treatment. In progress; target 2026-10-26. **S**
- Goals of care and a health care agent documented, and revisited as treatment changes. In progress; target 2026-09-21. **S**
- Complete first-line chemoimmunotherapy without grade 3 or higher toxicity. In progress; target 2026-10-26. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026), National Comprehensive Cancer Network
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1) (2022), NEJM Evidence
- Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021), American Society of Clinical Oncology (Journal of Clinical Oncology)

## Follow-up

- Cycles 4 to 7 as scheduled. Visit before cycle 8 with a restaging CT, HBV DNA and ALT. **S**
- Next scheduled visit 2026-09-21: periodic adult preventive visit. **S**
